3D generated image representing genes, reflecting Wheeler Bio's biologics and cell line development services as a biotech company

Advancing Discovery

A paradigm shift in the translation from discovery to CMC clinical supply. We are raising the bar in biologics development.

The Wheeler Difference

Wheeler Bio Speeds Up and Simplifies the Discovery-to-IND Process.

Wheeler Bio brings biologics drug innovators, discovery CROs, and CDMOs together to solve an outdated industry bottleneck with a unique partnering model, built on shared success and lasting collaborations. The typical momentum drop between discovery and development poses significant challenges for emerging biopharma companies adding technical, financial, and regulatory risks. We believe these lifecycle challenges can be reduced with more democratization of manufacturing platforms.

Wheeler is proud to currently offer best-in-class mammalian cell line and process development, GLP Tox material supply, and efficient CGMP clinical supply. Connect with our team today to learn more about how Wheeler can add value to your project.

Discover Wheeler Speak with Our Team

Get to IND Faster with Portable CMC®

With Portable CMC®, Wheeler is simplifying the connection between drug discovery and clinical supply by standardizing and democratizing the pathway from innovation to first-in-human clinical trials. A new bridge for translating discoveries to IND filing, innovators benefit from increased momentum during technology transfer, reduced risk, and modular work packages designed to fit timelines and budgets with ease.

Learn More

A Biomanufacturing Ecosystem

Protein Sciences & Portable CMC® Lab

Integrated Process Development Lab

Small Scale CGMP Manufacturing Facility

Boston, MA

Oklahoma City, OK

Oklahoma City, OK

  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Molecular Biology
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Transient Protein Production in HEK or CHO Cells
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Preclinical Material Supply & Testing from Stable CHO Pools
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Advanced Cell Line Engineering
Learn More
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Transient Protein Production in HEK or CHO Cells
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Stable Cell Line Development
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Preclinical Material Supply & Testing from Stable Pools
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Process Development & Optimization
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Process Characterization
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Analytical Development & Qualification
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Formulation Development
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Preclinical Material Supply & Testing from Stable Clones
Learn More
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    CGMP Master Cell Banking
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Grade C Solution Preparation
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    Grade D Ballroom Clinical Production Suites (50L and 500L Scale)
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    QC Testing & Release Powered by Charles River RightSource℠ Technology
  • a checkmark graphic, used to indicate the capabilities of Wheeler and its equipment at its cell line development facility in Boston
    CGMP Drug Substance Manufacturing
LEARN MORE

News + Events

Articles

How Synergistic Collaborations Between Outsourcing Partners Can Accele...

Blogs

From Vector Design to Process Characterization: A Biotech Journey

Articles

Leveraging Innovative Transposase Technology for a Highly Reliable and...

News + PR

ISPE Announces 2024 Facility of the Year Awards Submission Finalists

Blogs

8 Innovative Technologies Streamlining Early-Stage Antibody Development

Resources

Flyer: Introducing PHASE™ – A Premium Partnership in Biotech C...

Articles

Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler...

Videos

OKC Small-Scale CGMP Manufacturing Facility Tour

Events

BioInnovation Leaders Summit

Events

DCAT

Events

RESI South 2024

Events

PEGS Boston

Events

BIO Conference

Events

BPI Biotech Week

Events

BIO EU

Events

PEGS (EU)

Events

Antibody Engineering & Therapeutics

Videos

OKC CGMP Manufacturing Facility Grand Opening

Blogs

Benefits of operating within an innovation hub ecosystem

News + PR

Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering...

News + PR

Wheeler Bio Announces Grand Opening of Biomanufacturing Facility

Blogs

Top 5 Ways that Portable CMC® can Benefit your Antibody De...

Blogs

An agile approach streamlines the path to clinic for novel monoclonal ...

News + PR

Wheeler Bio Appoints Marc Helouin as Chief Quality and Regulatory Offi...

Articles

The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to...

Resources

Molecule to Market: Inside the Outsourcing Space

Videos

GBX Events Bio Innovation Leaders Summit 2023

Resources

Brochure: Closing the Gap Between Discovery and Development

Resources

Presentation: Solving for Speed in Translational CMC

Videos

Webinar: Solving for Speed in Translational CMC

Resources

Podcast: From Development to Manufacturing in Biologics

News + PR

Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer

News + PR

Wheeler Bio and Charles River Laboratories Announce Agreement to Build...

Blogs

Shortening mAb development timelines with accelerative CMC strategies

News + PR

Wheeler Bio Announces Closing of $31 Million Series A Round Supporting...

News + PR

Wheeler Bio Announces Initial Closing of Series A Round Supporting New...

Videos

Boston R&D Center

News + PR

Wheeler Bio Integrates the Solentim® Ecosystem by Advanced Instrument...

Videos

Wheeler 360⁰ Tour: Process Development Upstream

Articles

Applying an Advanced Pharma 4.0 Perspective to Design the Facility of ...

Articles

Reducing Time to IND, Increasing Quality, and Building Trust Through S...

News + PR

Wheeler Bio Announces $14M Seed Round To Expand Access To Portable CMC...

Proven Successes

“Working with Wheeler’s team of consummate professionals has enabled us to accelerate our development, enabling us to file our PIND and IND within a year. We have accomplished so much in such little time due to Wheeler’s knowledge, expertise, and constant engagement with our process. We look forward to partnering with Wheeler for many years to come.”

John B. Mumm Ph.D.

President & CEO at Deka Biosciences

“Wheeler’s team of process and analytical development experts have been very responsive to our needs in securing critical data for the scale-up of seviprotimut-L for our pivotal, Phase 3 confirmatory trial. Their attention to detail, rigorous scientific approach and collaborative nature has been well received by the Polynoma CMC team.”

Patrick J. Mallon

COO at Polynoma

“It’s been extremely valuable to be able to remain comfortably within the 82VS partner network and engage in early problem-solving discussions with world-class professionals as experienced as those at Wheeler Bio. We've had extremely fruitful discussions about stage-appropriate development solutions that can support the translation of our discovery pipeline into scalable processes and it has been and continues to be a pleasure engaging with the collaborative team at Wheeler.”

Andrew Peterson, Ph.D.

CEO at Broadwing Bio

“You have an awesome team!”

John Conner

CMO at Deka Biosciences

“Just wanted you to know what a wonderful experience I have had with Wheeler. Everyone answers the phone, answers my million questions and is so nice and professional! It was like in the old days – lol! Great job!”

Crystal Sanjenis

Wheeler Covid Lab customer

“We have been working with the Wheeler team for about a year now and it has been a great experience. They are extremely knowledgeable and have been helpful to our entire team.”

Samantha Conner

Vice President of Program Management at Deka Biosciences

Push Boundaries. Affect Change.

We are a growing team of drug development professionals who share a passion for speed to clinical impact through collaboration.

Connect with Us

"*" indicates required fields

* required fields

Submit